nach oben

Journal of General Internal Medicine

Erschienen in:

01.02.2016 | Perspective

Industry Support of Medical Research: Important Opportunity or Treacherous Pitfall?

verfasst von: William M. Tierney, MD, Eric M. Meslin, PhD, Kurt Kroenke, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Pharmaceutical and device manufacturers fund more than half of the medical research in the U.S. Research funding by for-profit companies has increased over the past 20 years, while federal funding has declined. Research funding from for-profit medical companies is seen as tainted by many academicians because of potential biases and prior misbehavior by both investigators and companies. Yet NIH is encouraging partnerships between the public and private sectors to enhance scientific discovery. There are instances, such as methods for improving drug adherence and post-marketing drug surveillance, where the interests of academician researchers and industry could be aligned. We provide examples of ethically performed industry-funded research and a set of principles and benchmarks for ethically credible academic–industry partnerships that could allow academic researchers, for-profit companies, and the public to benefit.

Moses H III, Matheson DHM, Cairns-Smith S, George BP, Palisch C, Dorsey R. The anatomy of medical research: US and international comparisons. JAMA. 2015;313:174–89.CrossRefPubMed

National Center for Advancing Translational Sciences. Discovering new therapeutic uses for existing molecules. Available at: http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/therapeutic-uses/therapeutic-uses.html. Accessed April 25, 2015.

National Institutes of Health. Accelerating medicines partnerships. Available at: http://www.nih.gov/science/amp/index.htm. Accessed April 25, 2015.

National Institutes of Health. NIH launches collaborative program with industry and researchers to spur therapeutic development. Available at: http://www.nih.gov/news/health/may2012/od-03.htm. Accessed April 25, 2015.

Patent and Trademark Law Amendments Act of 1980, Pub. L. No. 96–517, 94 Stat. 3015, 69331 (1980) (codified as amended at 35 U.S.C. ch. 30 (2011)).

Patient Protection and Affordable Care Act, Pub. L. No. 111–148, 124 Stat. 119 (2010); Sec. 6002: Transparency Reports and Reporting of Physician Ownership or Investment Interests (codified as 42 U.S.C.A. § 1320a-7h).

USInflation.org. US inflation rate calculator. Available at: http://usinflation.org/us-inflation-rate-calculator/. Accessed July 7, 2015.

Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials. 2012;13:138.PubMedCentralCrossRefPubMed

Farwell WR, Stump TE, Wang J, Tafesse E, L’Italien G, Tierney WM. Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med. 2004;19:1200–5.PubMedCentralCrossRefPubMed

10.

Psaty BM, Meslin EM, Breckenridge A. A lifecycle approach to the evaluation of FDA approval methods and actions: opportunities provided by a new IOM report. JAMA. 2012;307(23):2491–2.CrossRefPubMed

11.

Jain SH, Rosenblatt M, Duke J. Is big data the new frontier for academic-industry collaboration? JAMA. 2014;311:2171–2.CrossRefPubMed

12.

Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ. 2003;326:1171–3.PubMedCentralCrossRefPubMed

13.

Godlee F, Smith J, Marcovitch H. Wakefield’s article linking MR vaccine and autism was fraudulent. BMJ. 2011;342:c7452.CrossRefPubMed

14.

Cyranoski D. Research integrity: cell-induced stress. Nature. 2014;511(7508):140–3.CrossRefPubMed

15.

Hollon T. Researchers and regulators reflect on first gene therapy death. Nat Med. 2000;6:6.CrossRefPubMed

16.

Olsen AK, Whalen MD. Public perceptions of the pharmaceutical industry and drug safety: implications for the pharmacovigilance professional and the culture of safety. Drug Saf. 2009;32:805–10.CrossRefPubMed

17.

Kroenke K, Spitzer RL, Williams JBW, Löwe B. The Patient Health Questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32:345–59.CrossRefPubMed

18.

Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13.PubMedCentralCrossRefPubMed

19.

Web of Science. Available at: www.isiknowledge.com. Accessed April 25, 2015.

20.

McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247–63.CrossRefPubMed

21.

Newman JC, Feldman R. Copyright and open access at the bedside. N Engl J Med. 2011;365(26):2447–9.CrossRefPubMed

22.

Song F, Parekh S, Hooper L, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010;14:iii. ix-xi, 1–193.

23.

Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med. 2013;173:580–1.CrossRefPubMed

24.

Rennie D. Thyroid storm. JAMA. 1997;277:1238–43.CrossRefPubMed

25.

Blumenthal D, Campbell EG, Anderson MS, Causino N, Louis KS. Withholding research results by academic life scientists: evidence from a national survey of faculty. JAMA. 1997;277:1224–8.CrossRefPubMed

26.

Tierney WM, Gerrity MS. Scientific discourse, corporate ghostwriting, journal policy, and public trust. J Gen Intern Med. 2005;20:550–1.PubMedCentralCrossRefPubMed

27.

Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286:2947–55.CrossRefPubMed

28.

Krimsky S. Do financial conflicts of interest bias research? An inquiry into the “funding effect” hypothesis. Sci Technol Hum Values. 2013;38:566–87.CrossRef

29.

Sterne JA. Why the Cochrane risk of bias tool should not include funding source as a standard item. Cochrane Database Syst Rev. 2013;12:ED000076.PubMed

30.

Carpenter WT Jr, Koenig JI, Bilbe G, Bischoff S. At issue: a model for academic/industry collaboration. Schizophr Bull. 2004;30:997–1004.CrossRefPubMed

31.

Meslin EM, Gaffney MM, Quaid KA, Schwartz PH, Pitt AR, Rager JB. Final summary report: Review of the Merck-Regenstrief partnership. Available at: http://hdl.handle.net/1805/6044. Accessed July 7, 2015.

32.

Rosenbaum L. Beyond moral outrage – Weighing trade-offs of COI regulation. N Engl J Med. 2015;372:2064–8.CrossRefPubMed

33.

Steinbrook R, Kassirer JP, Angell M. Justifying conflicts of interest in medical journals: a very bad idea. BMJ. 2015;350:h2942.CrossRefPubMed

Titel: Industry Support of Medical Research: Important Opportunity or Treacherous Pitfall?
verfasst von: William M. Tierney, MD
Eric M. Meslin, PhD
Kurt Kroenke, MD
Publikationsdatum: 01.02.2016
Verlag: Springer US
Erschienen in: Journal of General Internal Medicine / Ausgabe 2/2016
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-015-3495-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2016

Hypertriglyceridemia-Induced Pancreatitis

Training Future Physicians to Deliver Tobacco Cessation Treatment

Use of Low Molecular Weight Heparins in Patients with Renal Failure; Time to Re-evaluate Our Preconceptions

Can Parsimonious Practice Please Patients and Practitioners? The Case of Spine Imaging

Oral Rehydration Therapy and Feeding Replaces Total Parenteral Nutrition: A Clinical Vignette